Endurant Capital Management’s AnaptysBio ANAB Stock Holding History

Endurant Capital Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-6,082	Closed	-$444K	–	54
2019 Q1	$444K	Sell	6,082 -6,652	-52%	-$459K	0.18%	62
2018 Q4	$812K	Buy	+12,734	New	+$947K	0.43%	41
2018 Q2	–	Sell	-3,130	Closed	-$326K	–	66
2018 Q1	$326K	Sell	3,130 -6,570	-68%	-$740K	0.12%	69
2017 Q4	$977K	Sell	9,700 -14,900	-61%	-$1.1M	0.3%	59
2017 Q3	$860K	Buy	+24,600	New	+$664K	0.26%	71
2017 Q2	–	Sell	-9,300	Closed	-$258K	–	93
2017 Q1	$258K	Buy	+9,300	New	+$217K	0.08%	83

Other funds holding ANAB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Endurant Capital Management's ANAB Position: Q2 2019 in Review

Endurant Capital Management sold out of AnaptysBio (ANAB) in Q2 2019, closing a stake of 6,082 shares — an estimated $444K sold.

Endurant Capital Management first reported a position in ANAB in Q1 2017 and held it in 6 quarters. The position peaked at $977K in Q4 2017. 127 funds tracked by Wall St. Rank hold ANAB as of Q2 2019.

Endurant Capital Management reported no remaining AnaptysBio position as of Q2 2019 after selling out during the quarter.
Endurant Capital Management sold 6,082 AnaptysBio shares in Q2 2019, an estimated $444K.
Endurant Capital Management first reported a position in AnaptysBio in Q1 2017 and held it in 6 quarters.
Endurant Capital Management's AnaptysBio position peaked at $977K in Q4 2017.
127 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2019.

Based on Endurant Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.